Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2012 (2012), Article ID 802384, 14 pages
http://dx.doi.org/10.1155/2012/802384
Review Article

The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury

1Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Esther Koplowitz Center, Roselló 149–153, 3rd Floor, Office 3.8, 08036 Barcelona, Spain
2Departamento de Patologia e Medicina Legal, Faculdade de Medicina, Universidade de Sao Paulo, 14049-900 Sao Paulo, SP, Brazil
3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 08036 Barcelona, Spain

Received 22 December 2011; Accepted 16 March 2012

Academic Editor: Stefan Alexson

Copyright © 2012 M. Elias-Miró et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Massip-salcedo, J. Roselló-Catafau, J. Prieto, M. A. Avíla, and C. Peralta, “The response of the hepatocyte to ischemia,” Liver International, vol. 27, no. 1, pp. 6–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Casillas-Ramírez, I. B. Mosbah, F. Ramalho, J. Roselló-Catafau, and C. Peralta, “Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation,” Life Sciences, vol. 79, no. 20, pp. 1881–1894, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Selzner and P. A. Clavien, “Fatty liver in liver transplantation and surgery,” Seminars in Liver Disease, vol. 21, no. 1, pp. 105–113, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Peralta and J. Roselló-Catafau, “The future of fatty livers,” Journal of Hepatology, vol. 41, no. 1, pp. 149–151, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. R. W. Busuttil and K. Tanaka, “The utility of marginal donors in liver transplantation,” Liver Transplantation, vol. 9, no. 7, pp. 651–663, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Kuboki, T. Shin, N. Huber et al., “Peroxisome proliferator-activated receptor-γ protects against hepatic ischemia/reperfusion injury in mice,” Hepatology, vol. 47, no. 1, pp. 215–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Akahori, M. Sho, K. Hamada et al., “Importance of peroxisome proliferator-activated receptor-γ in hepatic ischemia/reperfusion injury in mice,” Journal of Hepatology, vol. 47, no. 6, pp. 784–792, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Tailleux, K. Wouters, and B. Staels, “Roles of PPARs in NAFLD: potential therapeutic targets,” Biochimia et Biophysica Acta, vol. 1821, no. 5, pp. 809–818, 2012. View at Publisher · View at Google Scholar
  9. U. A. Boelsterli and M. Bedoucha, “Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: Insights from models of obesity and type 2 diabetes,” Biochemical Pharmacology, vol. 63, no. 1, pp. 1–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. C. N. Lumeng and A. R. Saltiel, “Inflammatory links between obesity and metabolic disease,” Journal of Clinical Investigation, vol. 121, no. 6, pp. 2111–2117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Yessoufou and W. Wahli, “Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels,” Swiss Medical Weekly, vol. 140, pp. w13071–w13080, 2010. View at Google Scholar · View at Scopus
  12. D. S. Straus and C. K. Glass, “Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms,” Trends in Immunology, vol. 28, no. 12, pp. 551–558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Massip-Salcedo, M. A. Zaouali, S. Padrissa-Altés et al., “Activation of peroxisome proliferator-activated receptor-α inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion,” Hepatology, vol. 47, no. 2, pp. 461–472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Casillas-Ramírez, I. Alfany-Fernández, M. Massip-Salcedo et al., “Retinol-binding protein 4 and peroxisome proliferator-activated receptor-γ in steatotic liver transplantation,” Journal of Pharmacology and Experimental Therapeutics, vol. 338, no. 1, pp. 143–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Y. Zhao, L. L. Jiang, L. Li, Z. J. Deng, B. L. Liang, and J. M. Li, “Peroxisome proliferator activated receptor-γ in pathogenesis of experimental fatty liver disease,” World Journal of Gastroenterology, vol. 10, no. 9, pp. 1329–1332, 2004. View at Google Scholar · View at Scopus
  16. M. Inoue, T. Ohtake, W. Motomura et al., “Increased expression of PPARγ in high fat diet-induced liver steatosis in mice,” Biochemical and Biophysical Research Communications, vol. 336, no. 1, pp. 215–222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Lanne, B. Dahllöf, C. Lindahl et al., “PPARα and PPARγ regulation of liver and adipose proteins in obese and dyslipidemic rodents,” Journal of Proteome Research, vol. 5, no. 8, pp. 1850–1859, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Duval, U. Thissen, S. Keshtkar et al., “Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57Bl/6 mice,” Diabetes, vol. 59, no. 12, pp. 3181–3191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Pettinelli and L. A. Videla, “Up-regulation of PPAR-γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 5, pp. 1424–1430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Pettinelli, T. del Pozo, J. Araya et al., “Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion,” Biochimica et Biophysica Acta, vol. 1792, no. 11, pp. 1080–1086, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ricote and C. K. Glass, “PPARs and molecular mechanisms of transrepression,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 926–935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. T. M. Willson, M. H. Lambert, and S. A. Kliewer, “Peroxisome proliferator-activated receptor γ and metabolic disease,” Annual Review of Biochemistry, vol. 70, pp. 341–367, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Okaya and A. B. Lentsch, “Peroxisome proliferator-activated receptor-α regulates postischemic liver injury,” American Journal of Physiology, vol. 286, no. 4, pp. G606–G612, 2004. View at Google Scholar · View at Scopus
  24. S. Q. Xu, Y. H. Li, S. H. Hu, K. Chen, and L. Y. Dong, “Effects of Wy14643 on hepatic ischemia reperfusion injury in rats,” World Journal of Gastroenterology, vol. 14, no. 45, pp. 6936–6942, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. N. C. Teoh, J. Williams, J. Hartley, J. Yu, R. S. McCuskey, and G. C. Farrell, “Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury,” Hepatology, vol. 51, no. 3, pp. 996–1006, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Gao, H. D. Connor, J. J. Lemasters, R. P. Mason, and R. G. Thurman, “Primary nonfunction of fatty livers produced by alcohol is associated with a new, antioxidant-insensitive free radical species,” Transplantation, vol. 59, no. 5, pp. 674–679, 1995. View at Google Scholar · View at Scopus
  27. M. D. Wheeler, M. Katuna, O. M. Smutney et al., “Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury,” Human Gene Therapy, vol. 12, no. 18, pp. 2167–2177, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Zúñiga, M. Cancino, F. Medina et al., “N-3 PUFA supplementation triggers PPAR-a activation and PPAR-a/NF-?B interaction: anti-inflammatory implications in liver ischemia-reperfusion injury,” PLoS One, vol. 16, no. 12, Article ID e28502, 2011. View at Google Scholar
  29. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. A. von Knethen and B. Brune, “PPARγ: an important regulator of monocyte/macrophage function,” Archivum Immunologiae et Therapiae Experimentalis, vol. 51, no. 4, pp. 219–226, 2003. View at Google Scholar
  31. F. S. Ramalho, I. Alfany-Fernandez, A. Casillas-Ramírez et al., “Are angiotensin II receptor antagonists useful strategies in steatotic and nonsteatotic livers in conditions of partial hepatectomy under ischemia-reperfusion?” Journal of Pharmacology and Experimental Therapeutics, vol. 329, no. 1, pp. 130–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. R. F. Saidi, J. Chang, and S. Verb, “The effect of methylprednisolone on warm ischemia-reperfusion injury in the liver,” American Journal of Surgery, vol. 193, no. 3, pp. 345–347, 2007. View at Google Scholar
  33. T. Yorimitsu and D. J. Klionsky, “Autophagy: molecular machinery for self-eating,” Cell Death and Differentiation, vol. 12, no. 2, pp. 1542–1552, 2005. View at Google Scholar
  34. M. A. Zaouali, S. Padrissa-Altés, I. B. Mosbah et al., “Improved rat steatotic and nonsteatotic liver preservation by the addition of epidermal growth factor and insulin-like growth factor-I to University of Wisconsin solution,” Liver Transplantation, vol. 16, no. 9, pp. 1098–1111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Casillas-Ramírez, A. Zaouali, S. Padrissa-Altés et al., “Insulin-like growth factor and epidermal growth factor treatment: New approaches to protecting steatotic livers against ischemia-reperfusion injury,” Endocrinology, vol. 150, no. 7, pp. 3153–3161, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Casillas-Ramírez, M. Amine-Zaouali, M. Massip-Salcedo et al., “Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury,” Critical Care Medicine, vol. 36, no. 4, pp. 1256–1266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Ip, G. C. Farrell, G. Robertson, P. Hall, R. Kirsch, and I. Leclercq, “Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice,” Hepatology, vol. 38, no. 1, pp. 123–132, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Ip, G. Farrell, P. Hall, G. Robertson, and I. Leclercq, “Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice,” Hepatology, vol. 39, no. 5, pp. 1286–1296, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Nagasawa, Y. Inada, S. Nakano et al., “Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet,” European Journal of Pharmacology, vol. 536, no. 1-2, pp. 182–191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Zabielski, A. Blachnio-Zabielska, M. Baranowski, M. Zendzian-Piotrowska, and J. Gorski, “Activation of PPARα by bezafibrate negatively affects de novo synthesis of sphingolipids in regenerating rat liver,” Prostaglandins and Other Lipid Mediators, vol. 93, no. 3-4, pp. 120–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Tanaka, K. Sano, A. Horiuchi, E. Tanaka, K. Kiyosawa, and T. Aoyama, “Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis,” Journal of Clinical Gastroenterology, vol. 42, no. 4, pp. 413–418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Capanni, F. Calella, M. R. Biagini et al., “Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 8, pp. 1143–1151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Spadaro, O. Magliocco, D. Spampinato et al., “Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease,” Digestive and Liver Disease, vol. 40, no. 3, pp. 194–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. F. S. Zhu, S. Liu, X. M. Chen, Z. G. Huang, and D. W. Zhang, “Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia,” World Journal of Gastroenterology, vol. 14, no. 41, pp. 6395–6400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Hatzitolios, C. Savopoulos, G. Lazaraki et al., “Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia,” Indian Journal of Gastroenterology, vol. 23, no. 4, pp. 131–134, 2004. View at Google Scholar · View at Scopus
  46. S. Kersten, J. Seydoux, J. M. Peters, F. J. Gonzalez, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting,” Journal of Clinical Investigation, vol. 103, no. 11, pp. 1489–1498, 1999. View at Google Scholar · View at Scopus
  47. S. P. Anderson, L. Yoon, E. B. Richard, C. S. Dunn, R. C. Cattley, and J. C. Corton, “Delayed liver regeneration in peroxisome proliferator-activated receptor-α-null mice,” Hepatology, vol. 36, no. 3, pp. 544–554, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Gavrilova, M. Haluzik, K. Matsusue et al., “Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass,” The Journal of Biological Chemistry, vol. 278, no. 36, pp. 34268–34276, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. I. García-Ruiz, C. Rodríguez-Juan, T. Díaz-Sanjuán, M. Á. Martínez, T. Muñoz-Yagüe, and J. A. Solís-Herruzo, “Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice,” Hepatology, vol. 46, no. 2, pp. 414–423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. P. Turmelle, O. Shikapwashya, S. Tu, P. W. Hruz, Q. Yan, and D. A. Rudnick, “Rosiglitazone inhibits mouse liver regeneration,” The FASEB Journal, vol. 20, no. 14, pp. 2609–2611, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Yu, K. Matsusue, P. Kashireddy et al., “Adipocyte-specific gene expression and adipogenicsteatosis in the mouse liver due to peroxisome proliferator-activated receptor ?1 (PPAR?1) overexpression,” The Journal of Biological Chemistry, vol. 278, no. 1, pp. 498–505, 2003. View at Google Scholar
  52. N. Enomoto, Y. Takei, M. Hirose et al., “Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-γ, pioglitazone,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 3, pp. 846–854, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 362, no. 18, pp. 1675–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Aoyama, K. Ikejima, K. Kon, K. Okumura, K. Arai, and S. Watanabe, “Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-Ay mice,” Hepatology, vol. 49, no. 5, pp. 1636–1644, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. M. Nan, F. Han, L. B. Kong et al., “Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice,” Scandinavian Journal of Gastroenterology, vol. 46, no. 3, pp. 358–369, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Matsusue, M. Haluzik, G. Lambert et al., “Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 737–747, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. S. S. T. Lee, T. Pineau, J. Drago et al., “Targeted disruption of the α isoform of the peroxisome proliferator- activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators,” Molecular and Cellular Biology, vol. 15, no. 6, pp. 3012–3022, 1995. View at Google Scholar · View at Scopus
  58. J. K. Reddy, “Nonalcoholic steatosis and steatohepatitis III. Peroxisomal β-oxidation, PPARα, and steatohepatitis,” American Journal of Physiology, vol. 281, no. 6, pp. G1333–G1339, 2001. View at Google Scholar · View at Scopus
  59. S. D. Clarke, “Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome,” Journal of Nutrition, vol. 131, no. 4, pp. 1129–1132, 2001. View at Google Scholar · View at Scopus
  60. J. Delarue, C. LeFoll, C. Corporeau, and D. Lucas, “N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?” Reproduction Nutrition Development, vol. 44, no. 3, pp. 289–299, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. B. Lombardo and A. G. Chicco, “Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review,” Journal of Nutritional Biochemistry, vol. 17, no. 1, pp. 1–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Neschen, I. Moore, W. Regittnig et al., “Contrasting effects of fish oil and safflower oil on hepatic peroxisomal and tissue lipid content,” American Journal of Physiology, vol. 282, no. 2, pp. E395–E401, 2002. View at Google Scholar · View at Scopus
  63. E. Shteyer, Y. Liao, L. J. Muglia, P. W. Hruz, and D. A. Rudnick, “Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice,” Hepatology, vol. 40, no. 6, pp. 1322–1332, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Ezaki, Y. Yoshida, Y. Saji et al., “Delayed liver regeneration after partial hepatectomy in adiponectin knockout mice,” Biochemical and Biophysical Research Communications, vol. 378, no. 1, pp. 68–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. M. A. Fernàndez, C. Albor, M. Ingelmo-Torres et al., “Caveolin-1 is essential for liver regeneration,” Science, vol. 313, no. 5793, pp. 1628–1632, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Walldorf, C. Hillebrand, H. Aurich et al., “Propranolol impairs liver regeneration after partial hepatectomy in C57Bl/6-mice by transient attenuation of hepatic lipid accumulation and increased apoptosis,” Scandinavian Journal of Gastroenterology, vol. 45, no. 4, pp. 468–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. E. Moran-Salvador, M. Lopez-Parra, V. Garcia-Alonso et al., “Role for PPAR? in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts,” The FASEB Journal, vol. 25, no. 8, pp. 2538–2550, 2011. View at Google Scholar
  68. M. Selzner and P. A. Clavien, “Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway,” Hepatology, vol. 31, no. 1, pp. 35–42, 2000. View at Google Scholar · View at Scopus
  69. S. Q. Yang, A. K. Mandal, J. Huang, and A. M. Diehl, “Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology,” Hepatology, vol. 34, no. 4 I, pp. 694–706, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. I. A. Leclercq, J. Field, and G. C. Farrell, “Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury,” Gastroenterology, vol. 124, no. 5, pp. 1451–1464, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Yamauchi, K. Uetsuka, T. Okada, H. Nakayama, and K. Doi, “Impaired liver regeneration after partial hepatectomy in db/db mice,” Experimental and Toxicologic Pathology, vol. 54, no. 4, pp. 281–286, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. R. A. DeAngelis, M. M. Markiewski, R. Taub, and J. D. Lambris, “A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-κB inhibitor, IκBα,” Hepatology, vol. 42, no. 5, pp. 1148–1157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. D. A. Rudnick, “Trimming the fat from liver regeneration,” Hepatology, vol. 42, no. 5, pp. 1001–1003, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. H. S. Lai and W. J. Chen, “Alterations of remnant liver carnitine palmitoyltransferase I activity and serum carnitine concentration after partial hepatectomy in rats,” Journal of Surgical Research, vol. 59, no. 6, pp. 754–758, 1995. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Aoyama, J. M. Peters, N. Iritani et al., “Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα),” The Journal of Biological Chemistry, vol. 273, no. 10, pp. 5678–5684, 1998. View at Publisher · View at Google Scholar · View at Scopus
  76. G. C. Farrell, “Probing Prometheus: fat fueling the fire?” Hepatology, vol. 40, no. 6, pp. 1252–1255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Chinetti, J. C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Y. Tsai, Y. S. Lin, T. S. Yeh et al., “Disrupted hepatic adiponectin signaling impairs liver regeneration of steatotic rats,” Chang Gung Medical Journal, vol. 34, no. 3, pp. 248–259, 2011. View at Google Scholar · View at Scopus
  79. K. Schoonjans and J. Auwerx, “Thiazolidinediones: an update,” The Lancet, vol. 355, no. 9208, pp. 1008–1010, 2000. View at Google Scholar · View at Scopus
  80. H. Yki-Jarvinen, “Thiazolidinediones,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Plutzky, “The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis.,” The American Journal of Cardiology, vol. 92, no. 4, pp. 34J–41J, 2003. View at Google Scholar · View at Scopus
  82. J. Kohlroser, J. Mathai, J. Reichheld, B. F. Banner, and H. L. Bonkovsky, “Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States food and drug administration,” American Journal of Gastroenterology, vol. 95, no. 1, pp. 272–276, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. K. G. Tolman, “Thiazolidinedione hepatotoxicity: a class effect?” International Journal of Clinical Practice, no. 113, pp. 29–34, 2000. View at Google Scholar · View at Scopus
  84. T. R. Marcy, M. L. Britton, and S. M. Blevins, “Second-generation thiazolidinediones and hepatotoxicity,” Annals of Pharmacotherapy, vol. 38, no. 9, pp. 1419–1423, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. A. A. Bulhak, C. Jung, C. G. Ostenson, J. O. Lundberg, P. O. Sjöquist, and J. Pernow, “PPAR-α activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-kinase/Akt and NO pathway,” American Journal of Physiology, vol. 296, no. 3, pp. H719–H727, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. C. G. Woods, A. M. Burns, B. U. Bradford et al., “WY-14,643-induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase,” Toxicological Sciences, vol. 98, no. 2, pp. 366–374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. A. E. Lovett-Racke, R. Z. Hussain, S. Northrop et al., “Peroxisome proliferator-activated receptor α agonists as therapy for autoimmune disease,” Journal of Immunology, vol. 172, no. 9, pp. 5790–5798, 2004. View at Google Scholar · View at Scopus
  88. I. Rusyn, S. Asakura, B. Pachkowski et al., “Expression of base excisionDNArepair genes is a sensitive biomarker for in vivo detection of chemical-induced chronic oxidative stress: identification of the molecular marker source of radicals responsible for DNA damage by peroxisome proliferators,” Cancer Research, vol. 64, no. 3, pp. 1050–1057, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. Li, L. K. Leung, H. P. Glauert, and B. T. Spear, “Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-κB activity,” Carcinogenesis, vol. 17, no. 11, pp. 2305–2309, 1996. View at Google Scholar · View at Scopus
  90. I. Rusyn, S. Yamashina, B. H. Segal et al., “Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are involved in triggering cell proliferation in the liver due to peroxisome proliferators,” Cancer Research, vol. 60, no. 17, pp. 4798–4803, 2000. View at Google Scholar · View at Scopus
  91. A. Serafín, J. Roselló-Catafau, N. Prats, E. Gelpí, J. Rodés, and C. Peralta, “Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion,” Hepatology, vol. 39, no. 3, pp. 688–698, 2004. View at Google Scholar
  92. M. Elias-Miró, M. Massip-Salcedo, M. Jimenez-Castro, and C. Peralta, “Does adiponectin benefit steatotic liver transplantation?” Liver Transplantation, vol. 17, no. 9, pp. 993–1004, 2011. View at Google Scholar
  93. M. B. Jimenez-Castro, A. Casillas-Ramírez, M. Massip-Salcedo et al., “Cyclic adenosine 3',5'-monophosphate in rat steatotic liver transplantation,” Liver Transplantation, vol. 17, no. 9, pp. 1099–1110, 2011. View at Google Scholar
  94. P. A. Clavien, M. Selzner, H. A. Rudiger et al., “A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning,” Annals of Surgery, vol. 238, no. 6, pp. 843–852, 2003. View at Google Scholar · View at Scopus
  95. A. Choukèr, A. Martignoni, R. Schauer et al., “Beneficial effects of ischemic preconditioning in patients undergoing hepatectomy: the role of neutrophils,” Archives of Surgery, vol. 140, no. 2, pp. 129–136, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. G. Nuzzo, F. Giuliante, M. Vellone et al., “Pedicle clamping with ischemic preconditioning in liver resection,” Liver Transplantation, vol. 10, supplement 1, no. 2, pp. S53–S57, 2004. View at Google Scholar · View at Scopus
  97. D. Azoulay, V. Lucidi, P. Andreani et al., “Ischemic preconditioning for major liver resection under vascular exclusion of the liver preserving the caval flow: a randomized prospective study,” Journal of the American College of Surgeons, vol. 202, no. 2, pp. 203–211, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. N. N. Rahbari, M. N. Wente, P. Schemmer et al., “Systematic review and meta-analysis of the effect of portal triad clamping on outcome after hepatic resection,” British Journal of Surgery, vol. 95, no. 4, pp. 424–432, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. D. Azoulay, M. Del Gaudio, P. Andreani et al., “Effects of 10 minutes of ischemic preconditioning of the cadaveric liver on the graft's preservation and function,” Annals of Surgery, vol. 242, no. 1, pp. 133–139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Cescon, G. L. Grazi, A. Grassi et al., “Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study,” Liver Transplantation, vol. 12, no. 4, pp. 628–635, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Amador, L. Grande, J. Martí et al., “Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial,” American Journal of Transplantation, vol. 7, no. 9, pp. 2180–2189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. B. Koneru, A. Shareef, G. Dikdan et al., “The ischemic preconditioning paradox in deceased donor liver transplantation—evidence from a prospective randomized single blind clinical trial,” American Journal of Transplantation, vol. 7, no. 12, pp. 2788–2796, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. P. A. Clavien, S. Yadav, D. Sindram, and R. C. Bentley, “Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans,” Annals of Surgery, vol. 232, no. 2, pp. 155–162, 2000. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Q. Li, L. J. Liang, J. F. Huang, and Z. Li, “Ischemic preconditioning protects liver from hepatectomy under hepatic inflow occlusion for hepatocellular carcinoma patients with cirrhosis,” World Journal of Gastroenterology, vol. 10, no. 17, pp. 2580–2584, 2004. View at Google Scholar · View at Scopus
  105. K. Yamagami, J. Hutter, Y. Yamamoto et al., “Synergistic effects of brain death and liver steatosis on the hepatic microcirculation,” Transplantation, vol. 80, no. 4, pp. 500–505, 2005. View at Publisher · View at Google Scholar · View at Scopus